Trabectedin for Recurrent Grade II or III Meningioma: a Randomized Phase II Study of the EORTC Brain Tumor Group
Phase of Trial: Phase II
Latest Information Update: 17 Jul 2017
At a glance
- Drugs Trabectedin (Primary)
- Indications Meningioma
- Focus Therapeutic Use
- 04 Feb 2016 New source identified and integrated (United Kingdom Clinical Research Network; 20311)
- 21 Sep 2015 According to EORTC and PharmaMar media release, company has enrolled first patient for this trial.
- 16 Jul 2015 Planned primary completion date changed from 1 Mar 2017 to 1 Jul 2017 as reported by ClinicalTrials.gov record.